PR96990

NANJING, China, July 14, 2022 /PRNewswire=KYODO JBN/ --

On July 13, 2022, Triastek, Inc. ("Triastek") announced a collaboration with

Eli Lilly and Company ("Lilly"), a leading global pharmaceutical company, to

leverage the advantages of 3D printing technology to enable precisely targeted

and programmed release of drugs in specific regions of the GI tract.

According to the agreement, the project will focus on the targeted release of

drugs in the intestine. Triastek will focus on two aspects: Firstly, conduct an

in-depth study of excipient properties and process parameters to maintain drug

stability throughout the formulation development and 3D printing process, as

well as during drug release. Secondly, identify a unique three-dimensional

structure dosage form design, that will permit programmed release of drugs in

specific parts of the intestine, with the goal of improving the bioavailability

of orally administered drugs.

Triastek is a 3D printing technology platform company, and its pioneering MED®

technology has versatile applications in solid dosage forms development and

manufacturing. With the facilitation of this collaboration by Lilly China

Innovation & Partnerships, Triastek will work with Lilly to explore novel

solutions to the oral delivery of drugs.

Triastek is committed to promoting the application of 3D printing technology in

the pharmaceutical field. Triastek's 1st and 2nd products (T19 and T20) have

received IND clearance from the U.S. Food and Drug Administration (FDA). The

company also holds 158 patent applications related to 3D printing of

pharmaceuticals with comprehensive patent coverage in the world. Triastek has

also established collaborations with a number of multinational pharmaceutical

companies, as well as domestic pharmaceutical companies to provide technical

solutions for the development of challenging formulations.

Dr. Senping Cheng, founder and CEO of Triastek, said: "the collaboration

between Triastek and Lilly is a great example of applying MED® technology for

improving the oral delivery of drugs. We envision that the MED® technology of

Triastek can be used to solve the challenges in formulations leading to the

development of clinically valuable products for our global partners."

Triastek

Founded in 2015, Triastek, Inc. is the global leader in the 3D printing of

pharmaceuticals and is pioneering the implementation of digital pharmaceutical

solutions. Triastek's novel and proprietary 3D printing technology platform,

encompasses dosage form design, digital pharmaceutical product development, and

intelligent manufacturing.

SOURCE: Triastek